IT1244647B - Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo. - Google Patents

Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo.

Info

Publication number
IT1244647B
IT1244647B ITRM910085A ITRM910085A IT1244647B IT 1244647 B IT1244647 B IT 1244647B IT RM910085 A ITRM910085 A IT RM910085A IT RM910085 A ITRM910085 A IT RM910085A IT 1244647 B IT1244647 B IT 1244647B
Authority
IT
Italy
Prior art keywords
quercitin
cancer therapy
ovarian
pharmaceutical product
active principle
Prior art date
Application number
ITRM910085A
Other languages
English (en)
Inventor
Salvatore Mancuso
Giovanni Scambia
Pier Luigi Benedetti-Panici
Mauro Piantelli
Franco Oreste Ranelletti
Arnaldo Capelli
Giancarlo Folchitto
Original Assignee
Salvatore Mancuso
Romeo Francesco
Dalla Costa Giorgio
Giancarlo Folchitto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvatore Mancuso, Romeo Francesco, Dalla Costa Giorgio, Giancarlo Folchitto filed Critical Salvatore Mancuso
Priority to ITRM910085A priority Critical patent/IT1244647B/it
Publication of ITRM910085A0 publication Critical patent/ITRM910085A0/it
Priority to JP4505072A priority patent/JPH07502009A/ja
Priority to AU12691/92A priority patent/AU1269192A/en
Priority to EP92905230A priority patent/EP0570475A1/en
Priority to PCT/IT1992/000007 priority patent/WO1992013851A1/en
Publication of ITRM910085A1 publication Critical patent/ITRM910085A1/it
Application granted granted Critical
Publication of IT1244647B publication Critical patent/IT1244647B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Si descrive un prodotto, utilizzabile nella terapia dei tumori, contenente almeno una delle seguenti sostanze:sale della quercitina con lo zinco,sale della quercitina col selenio,composto fluorurato della quercitina,composto glicosidico della quercitina.Tale prodotto è caratterizzato da un tempo di permanenza nell'organismo, e quindi da un'efficacia terapeutica, maggiore di quello della quercitina non legata.
ITRM910085A 1991-02-05 1991-02-05 Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo. IT1244647B (it)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ITRM910085A IT1244647B (it) 1991-02-05 1991-02-05 Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo.
JP4505072A JPH07502009A (ja) 1991-02-05 1992-01-31 クエルセチン化合物を活性物質として含有する腫瘍、特に卵巣及び造血系の腫瘍の治療用薬剤
AU12691/92A AU1269192A (en) 1991-02-05 1992-01-31 Pharmaceutical product for the therapy of tumors, particularly ovarian and haemopoietic system tumors, containing quercetin compounds as active substances
EP92905230A EP0570475A1 (en) 1991-02-05 1992-01-31 Pharmaceutical preparation for the therapy of tumors, particularly ovarian and haemopoietic system tumors, containing quercetin compounds as active substances
PCT/IT1992/000007 WO1992013851A1 (en) 1991-02-05 1992-01-31 Pharmaceutical product for the therapy of tumors, particularly ovarian and haemopoietic system tumors, containing quercetin compounds as active substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITRM910085A IT1244647B (it) 1991-02-05 1991-02-05 Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo.

Publications (3)

Publication Number Publication Date
ITRM910085A0 ITRM910085A0 (it) 1991-02-05
ITRM910085A1 ITRM910085A1 (it) 1992-08-05
IT1244647B true IT1244647B (it) 1994-08-08

Family

ID=11399834

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM910085A IT1244647B (it) 1991-02-05 1991-02-05 Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo.

Country Status (5)

Country Link
EP (1) EP0570475A1 (it)
JP (1) JPH07502009A (it)
AU (1) AU1269192A (it)
IT (1) IT1244647B (it)
WO (1) WO1992013851A1 (it)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20010600A1 (it) * 2001-10-04 2003-04-04 Brane Tech S R L Composti flavonoidici capaci di modificare lo stato fisico e/o dinamico di membrane biologiche e di stimolare la sintesi endogena di protein
JP2013543898A (ja) * 2010-11-24 2013-12-09 デュレクト コーポレイション 生体分解性薬物送達組成物
US9517249B2 (en) 2012-11-26 2016-12-13 Access Business Group International Llc Antioxidant dietary supplement and related method
CN111068095B (zh) * 2020-02-07 2021-07-13 中国科学院上海硅酸盐研究所 高效诱导烧伤创面毛囊再生的生物活性离子改性槲皮素螯合剂组合物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2892845A (en) * 1957-11-26 1959-06-30 Jurd Leonard Selective etherification of the 7-hydroxyl group in polyhydroxy flavonoids
FR3541M (fr) * 1964-05-12 1965-09-13 Laroche Navarron Lab Médicament a propriétés natriurétiques a base d'une nouvelle flavone.

Also Published As

Publication number Publication date
AU1269192A (en) 1992-09-07
WO1992013851A1 (en) 1992-08-20
JPH07502009A (ja) 1995-03-02
EP0570475A1 (en) 1993-11-24
ITRM910085A0 (it) 1991-02-05
ITRM910085A1 (it) 1992-08-05

Similar Documents

Publication Publication Date Title
MY111791A (en) Aqueous gel retinoid dosage form.
CO4700482A1 (es) Formulaciones de un analogo monomero de insulina
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
BG101118A (en) Therapeutical compounds
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
ATE495793T1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
CO4910145A1 (es) Uso
ES2126114T3 (es) Composiciones liquidas estables de interferon gamma.
DK0701440T3 (da) Tri(platin)komplekser
IT1244647B (it) Prodotto farmaceutico per la terapia dei tumori, in particolare di quelli ovarici e del sistema emopoietico, contenente quercitina come principio attivo.
IT1254995B (it) Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
MX9203361A (es) Composiciones farmaceuticas que contienen cloruro de galio.
UA49789C2 (uk) Застосування димеру лізоциму як лікарського засобу для інгібування біосинтезу фактора некрозу пухлини, спосіб лікування та профілактики захворювань (варіанти), фармацевтична композиція (варіанти), застосування димеру лізоциму як лікарського засобу для профілактики або лікування сніду
ITRM910730A1 (it) Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali.
TR200100611T2 (tr) İbuprofen ve domperidon içeren farmasötik kompozisyonlar
IT1241079B (it) Composizioni farmaceutiche contenenti ipriflavone,procedimento per la loro preparazione e relativo impiego terapeutico
ITMI932189A1 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
ATE293445T1 (de) Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
KR930702016A (ko) 골다공증 치료제
ITRM910155A1 (it) Preparati farmaceutici per la terapia dei tumori contenenti colchicina come principio attivo e metodi per l'impiego degli stessi
ES2052475T1 (es) Preparacion farmaceutica para el tratamiento de trastornos inmunoorganicos comprendiendo pp14 o anticuerpos pp14.
KR880008807A (ko) 정신병의 치료방법
MX9703839A (es) Soluciones intravenosas de lubeluzol.
SU1807595A1 (ru) Средство для лечения отравлений ртутью

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960215